Canada
· Delayed Price · Currency is CAD Kane Biotech Statistics
Total Valuation
Kane Biotech has a market cap or net worth of CAD 15.13 million. The enterprise value is 16.51 million.
| Market Cap | 15.13M |
| Enterprise Value | 16.51M |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Kane Biotech has 137.51 million shares outstanding. The number of shares has increased by 14.62% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 137.51M |
| Shares Change (YoY) | +14.62% |
| Shares Change (QoQ) | +19.85% |
| Owned by Insiders (%) | 38.01% |
| Owned by Institutions (%) | n/a |
| Float | 82.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.99 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 3.42 |
| EV / Sales | 21.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.84 |
Financial Position
The company has a current ratio of 0.82
| Current Ratio | 0.82 |
| Quick Ratio | 0.51 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.41 |
| Interest Coverage | -4.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -58.43% |
| Return on Capital (ROIC) | -160.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +83.33% in the last 52 weeks. The beta is 0.52, so Kane Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +83.33% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 44.42 |
| Average Volume (20 Days) | 71,456 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kane Biotech had revenue of CAD 757,114 and earned 4.83 million in profits. Earnings per share was 0.04.
| Revenue | 757,114 |
| Gross Profit | 458,338 |
| Operating Income | -4.51M |
| Pretax Income | -5.48M |
| Net Income | 4.83M |
| EBITDA | -4.47M |
| EBIT | -4.51M |
| Earnings Per Share (EPS) | 0.04 |
Balance Sheet
The company has 1.01 million in cash and 2.39 million in debt, giving a net cash position of -1.38 million or -0.01 per share.
| Cash & Cash Equivalents | 1.01M |
| Total Debt | 2.39M |
| Net Cash | -1.38M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -721,699 |
| Book Value Per Share | -0.01 |
| Working Capital | -501,441 |
Cash Flow
In the last 12 months, operating cash flow was -5.80 million and capital expenditures -24,474, giving a free cash flow of -5.82 million.
| Operating Cash Flow | -5.80M |
| Capital Expenditures | -24,474 |
| Free Cash Flow | -5.82M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 60.54%, with operating and profit margins of -596.18% and 637.45%.
| Gross Margin | 60.54% |
| Operating Margin | -596.18% |
| Pretax Margin | -723.31% |
| Profit Margin | 637.45% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -769.03% |
Dividends & Yields
Kane Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.62% |
| Shareholder Yield | -14.62% |
| Earnings Yield | 33.56% |
| FCF Yield | -38.49% |
Stock Splits
The last stock split was on March 13, 2017. It was a reverse split with a ratio of 0.2.
| Last Split Date | Mar 13, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Kane Biotech has an Altman Z-Score of -13.31. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.31 |
| Piotroski F-Score | n/a |